Lincocin (lincomycin) Disease Interactions
There are 4 disease interactions with Lincocin (lincomycin):
Mdvs (Includes Lincocin) ↔ Prematurity
Severe Potential Hazard, Moderate plausibility
Applies to: Prematurity/Underweight in Infancy
Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative. Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight. When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants. Thus, single-dose formulations should always be used in infants whenever possible. However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated. The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns. However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered. The level at which toxicity may occur is unknown.
- ""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997): 268-78
- "Product Information. Tracrium (atracurium)." Glaxo Wellcome, Research Triangle Park, NC.
- "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn, Kalamazoo, MI.
Antibiotics (Includes Lincocin) ↔ Colitis
Moderate Potential Hazard, High plausibility
Applies to: Colitis/Enteritis (Noninfectious)
Pseudomembranous colitis has been reported with most antibacterial agents and may range in severity from mild to life-threatening, with an onset of up to two months following cessation of therapy. Antibiotic therapy can alter the normal flora of the colon and permit overgrowth of Clostridium difficile, whose toxin is believed to be a primary cause of antibiotic- associated colitis. The colitis is usually characterized by severe, persistent diarrhea and severe abdominal cramps, and may be associated with the passage of blood and mucus. The most common culprits are clindamycin, lincomycin, the aminopenicillins (amoxicillin, ampicillin), and the cephalosporins. Therapy with broad-spectrum antibiotics and other agents with significant antibacterial activity should be administered cautiously in patients with a history of gastrointestinal diseases, particularly colitis. There is some evidence that pseudomembranous colitis, if it occurs, may run a more severe course in these patients and that it may be associated with flares in their underlying disease activity. The offending antibiotic(s) should be discontinued if significant diarrhea occurs during therapy. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. A large bowel endoscopy may be considered to establish a definitive diagnosis in cases of severe diarrhea.
- Moriarty HJ, Scobie BA "Pseudomembranous colitis in a patient on rifampicin and ethambutol." N Z Med J 04/23/80 (1980): 294-5
- Thomas E, Mehta JB "Pseudomembranous colitis due to oxacillin therapy." South Med J 77 (1984): 532-3
- Harmon T, Burkhart G, Applebaum H "Perforated pseudomembranous colitis in the breast-fed infant." J Pediatr Surg 27 (1992): 744-6
Lincomycin (Includes Lincocin) ↔ Asthma
Moderate Potential Hazard, Moderate plausibility
Applies to: Asthma
Lincomycin should be used with caution in patients with a history of asthma or significant allergies.
Lincomycin (Includes Lincocin) ↔ Renal/Liver Disease
Moderate Potential Hazard, High plausibility
Applies to: Liver Disease, Renal Dysfunction
Lincomycin is partially metabolized by the liver and eliminated in the urine, bile and feces as both parent drug and metabolites. The serum concentration of lincomycin may be increased and the half-life prolonged in patients with renal and/or liver disease. Therapy with lincomycin should be administered cautiously in patients with significantly impaired renal and/or hepatic function. In patients with severe renal impairment (CrCl < 10 mL/min), the manufacturer recommends using 25% to 30% of the normal dosage. Due to inadequate data in patients with liver disease, the manufacturer does not recommend its use except under special clinical circumstances. Periodic renal and liver function tests should be performed during prolonged therapy.
- "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn, Kalamazoo, MI.
Lincocin (lincomycin) drug Interactions
There are 37 drug interactions with Lincocin (lincomycin)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.